<DOC>
	<DOC>NCT00532974</DOC>
	<brief_summary>The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL epitope DNA vaccine (EP1090) in HIV-1 infected individuals receiving potent combination antiretroviral therapy (ART) and who have undetectable levels of viral replication in plasma.</brief_summary>
	<brief_title>A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV1 Infection CD4 Tcell count &gt;350 HIV1 RNA levels to &lt;400 copies Negative HbsAg and antiHCV antibody Recent receipt of experimental HIV1 vaccines Recent use of immunomodulatory agents Hypersensitivity or serious reactions to study vaccine components Active opportunistic infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>HIV</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Vaccines</keyword>
	<keyword>HIV Vaccines</keyword>
	<keyword>Peptide</keyword>
	<keyword>Peptide Vaccines</keyword>
	<keyword>HIV 1</keyword>
</DOC>